PrintThe Burrill Report
The Burrill Report (January 17, 2012): Why Regenerative Medicine Might Fix Healthcare (.MP3,17.59 Mb)
The rising cost of healthcare is being driven in part by aging populations around the world and the growing incidence of chronic diseases. Some argue that the only way we will reign in cost is through innovation rather than cost cutting care. We spoke to Gil Van Bokkelen, chairman of the Alliance for Regenerative Medicine and Chairman and CEO of Athersys, about the role regenerative medicine can play in addressing these problems, the landscape today, and the challenges these companies face in funding innovative therapies in the current environment.
January 12, 2012
http://www.burrillreport.com/article-why_regenerative_medicine_might_fix_healthcare.html
REGENERATIVE MEDICINE
Why Regenerative Medicine Might Fix Healthcare
Podcast: January 17, 2012[Please login to post comments]
- Burrill & Company Indices
Read More - Biggest Market Movers
Read More - Cutting Healthcare Spending with Occam’s Razor
Looking at the most obvious places to address rising costs. Read More - Drugs in Bugs
With up to $125 million in committed funding, Warp Drive Bio will use genomics to discover and develop new drugs from natural products. Read More - Genentech Partners with Xenon Pharmaceuticals in $646M Pain Pact
Deal highlights growing interest in personalized medicine approaches to drug development. Read More - Forma Therapeutics Inks Alliance with Janssen Biotech
Tumor-focused deal expands Forma’s growing link with Big Pharma. Read More - Novartis to Ax 2,000 jobs after Tekturna Development Halted
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Flagship Ventures Launches $270 Million Fund
Life sciences companies see more venture capital coming their way. Read More - Bristol-Myers Squibb Buys Inhibitex for $2.5 Billion
Hepatitis C players remain hot targets Read More - Biotech Investors Get Their War Face On for JPMorgan
Podcast: January 9, 2012 Read More
.gif)
